848691-22-5

Basic information

• Product Name: Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-amino-
• Synonyms: Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-amino-;5-AMinothiazolo[4,5-d]pyriMidin-2(3H)-one;Thiazolo[4,5-d]pyrimidin-2(3H)-one
• CAS NO: 848691-22-5
• Molecular Formula: C₅H₄N₄OS
• Molecular Weight: 168.18
• Mol File: 848691-22-5.mol

Chemical Properties

• Appearance: /
• Density: 1.694±0.06 g/cm3(Predicted)
• PKA: 7.29±0.20(Predicted)
• CAS DataBase Reference: Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-amino-(CAS DataBase Reference)
• NIST Chemistry Reference: Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-amino-(848691-22-5)
• EPA Substance Registry System: Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-amino-(848691-22-5)

Safety Data

• Hazardous Substances Data: 848691-22-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-aminois used as a research compound for exploring its potential biological activity and pharmaceutical applications. Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-amino-'s core structure and associated chemical properties make it a promising candidate for further investigation in the development of new medicines.
Used in Drug Development:
Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-aminois used as a starting material or intermediate in the synthesis of more complex molecules with potential therapeutic effects. Its presence in the thiazolo[4,5-d]pyrimidines chemical class suggests that it may contribute to the creation of novel drugs with improved efficacy and safety profiles. However, specific details regarding its function, reactivity, or potential uses are not widely published or understood, indicating that it may require further experimental investigation to fully understand its potential in drug development.

Upstream product

• 55359-96-1 4-chloro-2-oxo-2,3-dihydrothiazole-5-carbaldehyde 
• 50-01-1 guanidine hydrochloride 
• 892498-86-1 5-amino-3H-thiazolo[4,5-d]pyrimidine-2-thione 

Relevant articles and documents

Development of a robust and sustainable process for nucleoside formation

A practical and robust process for the synthesis of an Isatoribine pro-drug was demonstrated. The process relies on a streamlined glycosylation carried out in xylene and an effective regioselective enzymatic hydrolysis that can be run in a semicontinuous way. Analysis of the process mass intensity established the high impact from an environmental standpoint of our process improvement.

Discovery of ANA975: An oral prodrug of the TLR-7 agonist isatoribine

ANA975, a 5-amino-3-β-D-ribofuranosyl-3H-thiazolo[4,5-d]pyrimidin-2- one derivative, was synthesized in the search of an oral prodrug of isatoribine, a small molecule toll-like receptor 7 (TLR-7) agonist. Several strategies were studied to enable the kilogram-scale synthesis of ANA975. Three general total syntheses are described. In the phase I clinical study of ANA975 against hepatitis C virus (HCV), conversion to isatoribine in plasma was rapid and effective, delivering levels of isatoribine that have been shown to be clinically relevant. Copyright Taylor & Francis Group, LLC.

Novel process for the preparation of 5-amino-3H-thiazolo[4,5-d]pyrimidin-2-one

The present invention relates to a process for the preparation of the title compound, 5-amino-3H-thiazolo[4,5-d]pyrimidin-2-one, which is a useful intermediate in the preparation of certain thiazolo[4,5-d]pyrimidine nucleosides, which can have utility as immunomodulators.

3-B-D-ribofuranosylthiazolo [4,5-d] pyridimine nucleosides and uses thereof

The invention is directed to 3-β-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds.

3-β-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF

The invention is directed to 3-?-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds.